Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald ...

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...

Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established heart failure drug Entresto and multiple sclerosis drug Kesimpta.

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) and Leqvio (+114% cc) Core operating income ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

Nestle India reported a quarterly profit below market expectations on Friday, as a slowdown in consumer spending in major ...

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...

Super Bowl LIX is already proving to offer serious star power, with ad spots led by Chris Pratt, Eugene Levy, Michelle ...